Agents useful for the treatment of various metabolic disorders, such as
insulin resistance syndrome, diabetes, poly-cystic ovary syndrome,
hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis
and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3,
or 4; q is 0 or 1; t is 0 or 1; R.sup.1 is alkyl having from 1 to 3
carbon atoms; R.sup.2 is hydrogen, halo, alkyl having from 1 to 3 carbon
atoms, or alkoxy having from 1 to 3 carbon atoms; one of R.sup.3 and
R.sup.4 is hydrogen or hydroxy and the other is hydrogen; or R.sup.3 and
R.sup.4 together are .dbd.O; R.sup.5 is hydrogen or alkyl having one,
two, three, four or five carbon atoms; A is phenyl, unsubstituted or
substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1
or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms,
and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms
wherein the cycloalkyl is unsubstituted or one or two ring carbons are
independently mono-substituted by methyl or ethyl; or a 5 or 6 membered
heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and
O and the heteroaromatic ring is covalently bound to the remainder of the
compound of formula I by a ring carbon. Alternatively, the. agent can be
a pharmaceutically acceptable salt of the compound of Formula I.